Latest Content

Review the latest in psychiatry from the last week.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.

Recognize postpartum psychosis fast: early signs, key risk factors, OCD vs delusions, and evidence-based lithium-centered treatment for urgent care.

Explore 2026 psychiatry practice M&A: surging demand, selective buyers, valuation premiums for scale, and the workforce/parity rules reshaping deals.

FDA approves Takeda’s Orzeyful, first orexin agonist, improving wakefulness and reducing cataplexy in adults with narcolepsy type 1 in pivotal trials.

Explore suicide prevention in psychiatry—risk assessment, treatment challenges, and emerging research. Submit your case or CME for August 2026.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

Two psychiatrists use poetry and therapy to unpack clinician trauma, residency transformation, and how discomfort becomes a tool for patient connection.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Learn how clinicians reframe side effects, curb nocebo, and boost outcomes using expectation, open-label placebos, and conditioning in psychiatry.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.